🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK — grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≤24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months — use filters for patent-cliff planning.

Page 4 of 18

  1. US 12012444

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12010979

    Non-human animals comprising a humanized TTR locus and methods of use

    Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12012445

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11999799

    Anti-TMPRSS2 antibodies and antigen-binding fragments

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12000839

    Methods for characterizing disulfide bonds

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11999777

    Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11986511

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11975045

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11964016

    Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11965161

    Methods and compositions for sensitization of tumor cells to immune therapy

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11965020

    Antigen binding molecule formats

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11958894

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11957687

    Modulators of HSD17B13 and methods of use thereof

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11957704

    Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11958910

    Bispecific antigen binding molecules that bind HER2, and methods of use thereof

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11951216

    Polymer protein microparticles

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11945872

    Anti-ACVR1 antibodies and uses thereof

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11944666

    Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion protein

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11932692

    Methods of treating cancer pain by administering a PD-1 inhibitor

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11926661

    Human antibodies to artemin and methods of use thereof

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11926668

    Anti-PD-1 antibodies for treatment of lung cancer

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11926670

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11919972

    Peptide libraries with non-canonical amino acids

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11919965

    Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11910787

    Rodents having a humanized TMPRSS gene

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11912767

    EGFR × CD28 multispecific antibodies

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11910788

    Mouse having a humanized cluster of differentiation 47 gene

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11905332

    Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11904017

    Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11896682

    Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof

    Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11897945

    Methods of treating allergy using anti-Bet v 1 antibodies

    Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11891607

    Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors

    Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11884736

    Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11884707

    Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11865134

    Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11866794

    Cas-ready mouse embryonic stem cells and mice and uses thereof

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11866502

    Anti-FGFR2 antibodies and methods of use thereof

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11866503

    Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11850535

    Methods for quantitating individual antibodies from a mixture

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11845963

    HSD17B13 variants and uses thereof

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11845957

    Models of tauopathy

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11844765

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11845931

    CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11845989

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11845800

    Methods for treating or preventing asthma by administering an IL-4R antagonist

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11834500

    Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11834485

    IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11826386

    Compositions and methods for treating cancer

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.